Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)-Reference-Cited by-同舟云学术

Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)

Published:2013-09-12 Issue:11 Volume:122 Page:1974-1982
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Saber Wael¹,Cutler Corey S.²,Nakamura Ryotaro³,Zhang Mei-Jie¹,Atallah Ehab⁴,Rizzo J. Douglas¹,Maziarz Richard T.⁵,Cortes Jorge⁶,Kalaycio Matt E.⁷,Horowitz Mary M.¹

Affiliation:

1. Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI;

2. Dana Farber Cancer Institute, Boston, MA;

3. City of Hope National Medical Center, Duarte, CA;

4. Medical College of Wisconsin, Milwaukee, WI;

5. Oregon Health & Science University, Portland, OR;

6. MD Anderson Cancer Center, Houston, TX; and

7. Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Abstract

Key Points For patients with acute myelogenous leukemia, post-transplant survival is not determined by donor source (unrelated vs related). However, for patients with myelodysplastic syndromes, donor source remains an important determinant of post-transplantation outcomes.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/122/11/1974/1331359/1974.pdf

Reference50 articles.

1. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management.;Garcia-Manero;Am J Hematol,2012

2. International scoring system for evaluating prognosis in myelodysplastic syndromes.;Greenberg;Blood,1997

3. Revised international prognostic scoring system for myelodysplastic syndromes.;Greenberg;Blood,2012

4. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.;Cutler;Blood,2004

5. A decision analysis of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for older patients with de-novo myelodysplastic syndrome (MDS): early transplantation offers survival benefit in higher-risk MDS.;Koreth;Blood,2011

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current challenges in conditioning regimens for MDS transplantation;Blood Reviews;2024-09

2. Prévention de la rechute des leucémies aiguës et syndromes myélodysplasiques en post-allogreffe : stratégies prophylactique et préemptive (SFGM-TC);Bulletin du Cancer;2024-09

3. Comparison of Older Related versus Younger Unrelated Donors for Older Recipients of Allogeneic Hematopoietic Cell Transplantation with Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Large Single-Center Analysis;Transplantation and Cellular Therapy;2024-07

4. Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy;Bone Marrow Transplantation;2024-05-07

5. Advances in the management of higher-risk myelodysplastic syndromes: future prospects;Leukemia & Lymphoma;2024-05-07